drugset / Trial / NCT04669808
Open Label, Dose Escalation Study for the Safety and Efficacy of STP705 in Adult Patients With Basal Cell Carcinoma
Non-randomizedSequentialOpen-labelTreatment
Summary
This phase 2, open label, dose escalation study is designed to evaluate the safety, tolerability and efficacy of various doses of STP705 administered as localized injection in patients with Basal Cell Carcinoma (BCC). Goals: * To determine the safe and effective recommended dose of STP705 for the treatment of basal cell carcinoma. * Analysis of biomarkers common to BCC formation pathway including TGF-β1 and COX-2.
Timeline
- Start
- 2020-12-28
- Primary completion
- 2023-02-09
- Completion
- 2023-02-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | STP705 | Small interfering RNA (siRNA) | 30 ug | Other |
| Subject | STP705 | Small interfering RNA (siRNA) | 60 ug | Other |
| Subject | STP705 | Small interfering RNA (siRNA) | 90 ug | Other |
| Subject | STP705 | Small interfering RNA (siRNA) | 120 ug | Other |
| Subject | STP705 | Small interfering RNA (siRNA) | 180 ug | Other |
| Subject | STP705 | Small interfering RNA (siRNA) | 240 ug | Other |
| Subject | STP705 | Small interfering RNA (siRNA) | 320 ug | Other |